{"id":19,"date":"2024-04-16T12:42:14","date_gmt":"2024-04-16T10:42:14","guid":{"rendered":"https:\/\/adaro.es\/CeloxPPH\/?page_id=19"},"modified":"2024-07-03T08:49:56","modified_gmt":"2024-07-03T06:49:56","slug":"evidencia-clinica","status":"publish","type":"page","link":"https:\/\/adaro.es\/CeloxPPH\/evidencia-clinica\/","title":{"rendered":"Evidencia Cl\u00ednica"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; next_background_color=\u00bb#ffd32a\u00bb _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#fafafa\u00bb background_image=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/headpic_clinic.jpg\u00bb min_height=\u00bb484px\u00bb custom_padding=\u00bb0px||0px||false|false\u00bb bottom_divider_style=\u00bbarrow2&#8243; global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_2,1_2&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb0px|auto|0px|127px|false|false\u00bb custom_padding=\u00bb0px||0px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bbrgba(28,0,0,0.3)\u00bb custom_padding=\u00bb0px||0px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_text_color=\u00bb#FFFFFF\u00bb text_font_size=\u00bb44px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb||0px|||\u00bb custom_padding=\u00bb25px|25px|25px|25px|false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p><b>CELOX&#x2122; PPH<\/b><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_text_color=\u00bb#FFFFFF\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb||-8px|||\u00bb custom_padding=\u00bb25px|25px|25px|25px|false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Una d\u00e9cada de resultados confiables en entornos de atenci\u00f3n m\u00e9dica del mundo real para un control y tratamiento altamente efectivo de la HPP uterina<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb0px||0px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#ffd32a\u00bb custom_margin=\u00bb0px|||||\u00bb custom_padding=\u00bb||18px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_3,1_3,1_3&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-38px|auto||auto||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/accelerate_12616582.png\u00bb _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb23%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb||18px|||\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#000000&#8243; text_font_size=\u00bb24px\u00bb text_line_height=\u00bb1.1em\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p style=\"text-align: center\"><span>ACCI\u00d3N<br \/><\/span><strong>R\u00c1PIDA<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/verified_2438078.png\u00bb title_text=\u00bbverified_2438078&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb23%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb||18px|||\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#000000&#8243; text_font_size=\u00bb24px\u00bb text_line_height=\u00bb1.1em\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p style=\"text-align: center\"><span><strong>SEGURO<\/strong>\u00a0<br \/>Y CL\u00cdNICAMENTE EFICAZ<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/thought_775497.png\u00bb title_text=\u00bbthought_775497&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb23%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb||18px|||\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#000000&#8243; text_font_size=\u00bb24px\u00bb text_line_height=\u00bb1.1em\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p style=\"text-align: center\"><strong><span>VERS\u00c1TIL<\/span><\/strong><span>\u00a0<br \/>Y F\u00c1CIL DE USAR<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#ccdddd\u00bb custom_padding=\u00bb36px||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p><strong><\/strong>12 a\u00f1os de eficacia cl\u00ednica (dentro de aplicaciones de HPP) frente al est\u00e1ndar de atenci\u00f3n, lo que demuestra una tecnolog\u00eda <strong>segura y cl\u00ednicamente eficaz<\/strong><\/p>\n<p>[\/et_pb_text][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/evidence-timeline-new.png\u00bb title_text=\u00bbevidence-timeline-new\u00bb _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p><strong><span>Los datos cl\u00ednicos de CELOX PPH respaldan las siguientes afirmaciones:<\/span><\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_3,1_3,1_3&#8243; use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb1&#8243; make_equal=\u00bbon\u00bb _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb min_height=\u00bb140px\u00bb custom_padding=\u00bb20px|20px|20px|20px|false|false\u00bb border_width_right=\u00bb1px\u00bb border_width_bottom=\u00bb1px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p><span>\u201cCELOX PPH es altamente eficaz en el control y tratamiento de la HPP uterina\u201d<\/span><span><\/span><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb min_height=\u00bb140px\u00bb custom_padding=\u00bb20px|20px|20px|20px|false|false\u00bb border_width_right=\u00bb1px\u00bb border_width_bottom=\u00bb1px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>\u201cCELOX PPH logr\u00f3 una tasa de \u00e9xito del 95,6% en hemostasia para sangrados de grado 1 a 3 (partos vaginales)\u201d (1)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb min_height=\u00bb140px\u00bb custom_padding=\u00bb20px|20px|20px|20px|false|false\u00bb border_width_right=\u00bb1px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>\u201cCELOX PPH consigue la hemostasia y evita un tratamiento quir\u00fargico posterior\u201d (2, 3, 4)<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb min_height=\u00bb140px\u00bb custom_padding=\u00bb20px|20px|20px|20px|false|false\u00bb border_width_bottom=\u00bb1px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>\u201cCELOX PPH logr\u00f3 una tasa de \u00e9xito del 100% de hemostasia para sangrado de grado 1 y 2 (hasta 2500 ml)\u201d (1)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb min_height=\u00bb140px\u00bb custom_padding=\u00bb20px|20px|20px|20px|false|false\u00bb border_width_bottom=\u00bb1px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>\u201cEl uso de CELOX PPH produce una reducci\u00f3n de las tasas de histerectom\u00eda de hasta un 78%\u201d (2, 3, 4)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb min_height=\u00bb140px\u00bb custom_padding=\u00bb20px|20px|20px|20px|false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>\u201cPuede utilizarse con pacientes en tratamiento anticoagulante o con coagulopat\u00eda inducida por traumatismos\u201d (1)<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/pdf-sheets.png\u00bb title_text=\u00bbpdf-sheets\u00bb _builder_version=\u00bb4.23&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#f2f2f2&#8243; global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.1.pdf\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb url_new_window=\u00bbon\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.1-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.1&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.1.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>RETROSPECTIVE ANALYSIS STUDY (N=102) ON THE USE OF CELOX PPH GAUZE AS A TREATMENT FOR PPH COMPARED WITH CURRENT STANDARD OF CARE<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Postpartum Haemorrhage:<br \/>CELOX&#x2122; PPH Gauze retrospective data analysis report (Charit\u00e9 data).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Henrich, W, D\u00fcckelmann A, Giroud D, Sarr Y. Version 1.1 \u2013 19 May 2022.<br \/>Retrospective analysis study (n=102)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Assessment of 102 patients with PPH who did not respond to conventional treatments<\/li>\n<li>Primary objective: to control uterine bleeding in PPH with CELOX&#x2122; PPH<\/li>\n<li>CELOX&#x2122; PPH demonstrated 100% successful haemostasis in all patients with grade 1 and 2 bleeds (up to 2500mls) for all deliveries<\/li>\n<li>CELOX&#x2122; PPH demonstrated 95.7% successful haemostasis in all patients with grade 1 to 3 bleeds (up to 8000mls) for vaginal deliveries<\/li>\n<li>Following the introduction of CELOX&#x2122; PPH the incidence of hysterectomies was significantly reduced (versus standard of care) by 77.8%<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.2.pdf\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb url_new_window=\u00bbon\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.2-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.2&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.2.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>RETROSPECTIVE COHORT STUDY (N=78) COMPARING OUTCOMES IN PPH MANAGEMENT USING CELOX PPH GAUZE VERSUS BALLOON TAMPONADE<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Uterine packing with CELOX&#x2122; PPH compared to balloon tamponade for managing postpartum haemorrhage.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Dueckelmann AM, Hinkson L, Nonnenmacher A, Siedentopf JP, Schoenborn I, Weizsaecker K, Kaufner L, Henrich W, Braun T. Eur J Obstet Gynecol Reprod Biol. 2019; 240:151-155.<\/p>\n<p><span>Retrospective cohort study (n=78)<\/span><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Assessment of the effectiveness and safety of CELOX&#x2122; PPH versus balloon tamponade for managing severe PPH<\/li>\n<li>CELOX&#x2122; PPH is an excellent treatment for severe PPH and is at least equivalent to the balloon tamponade<\/li>\n<li>Following the introduction of CELOX&#x2122; PPH the incidence of hysterectomies (versus standard of care) was reduced by 50%<\/li>\n<li>CELOX&#x2122; PPH is particularly effective in managing PPH resulting from uterine atony or placenta bed bleeding following vaginal or caesarean section deliveries.<\/li>\n<li>CELOX&#x2122; PPH is especially beneficial for cases involving lower uterine segment atony, placenta previa bed bleeding, and coagulopathy.<\/li>\n<li>No adverse events or treatment-related morbidity were linked to CELOX&#x2122; PPH<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.3.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.3-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.3&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.3.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>RANDOMISED, PROSPECTIVE EVALUATION (N=61) COMPARING THE EFFECTIVENESS OF CELOX GAUZE WITH BALLOON TAMPONADE IN PATIENTS WITH PPH<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Comparison of CELOX&#x2122; PPH and Bakri balloon in management of primary atonic postpartum Haemorrhage.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Von Beckerath AK, Maul H, Elmohandes AM, Shaaban M, Habib DM, Nasr A, Abdel-Kawi AF. Am J Obstet Gynecol. 2016; 214(1 Suppl 1):S335. [poster presentation]<\/p>\n<p>Randomised, prospective study (n=61)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Assessment of the effectiveness of intrauterine insertion of CELOX&#x2122; PPH in comparison to Bakri balloon<\/li>\n<li>Failure rate which led to peripartum hysterectomies were 9.7% (3\/31) in the CELOX&#x2122; PPH group compared to 40% (12\/30) in the Bakri balloon group<\/li>\n<li>CELOX&#x2122; PPH is a potentially effective treatment in the management of atonic PPH<\/li>\n<li>CELOX&#x2122; PPH is cost effective, and is easy to use compared to the standard balloon therapy<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.4.pdf\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.4-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.4&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.4.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>HISTORICAL, RETROSPECTIVE COHORT STUDY EVALUATION (N=666) COMPARING THE EFFECTIVENESS OF CHITOSAN COVERED (CELOX PPH) GAUZE WITH BALLOON TAMPONADE OR MEDICAL THERAPY IN PATIENTS WITH PPH<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Does the use of CELOX&#x2122; PPH for postpartum haemorrhage reduce the need for surgical therapy including hysterectomy? A databased historical cohort study.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Biele C, Radtke L, Kaufner L, Hinkson L, Braun T, Henrich W, D\u00fcckelmann AM. J Perinat Med. 2022; 50(8):1078-1086.<\/p>\n<p>Retrospective cohort study (n=666)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Assessment of the effectiveness of CELOX&#x2122; PPH in comparison with balloon tamponade, and medical therapy only<\/li>\n<li>Groups were compared in terms of therapy success, side-effects, and the primary outcome was the need for surgical measures (e.g., hysterectomy)<\/li>\n<li>No significant differences in the need for surgical therapy between groups.<br \/>CELOX&#x2122; PPH group had significantly fewer hysterectomies compared to the balloon tamponade group.<\/li>\n<li>Following the introduction of CELOX&#x2122; PPH, the incidence of PPH-related hysterectomies was significantly reduced by 77.8%.<\/li>\n<li>No adverse events related to CELOX&#x2122; PPH<\/li>\n<li>CELOX&#x2122; PPH is easy to use and cost-effective compared to alternative devices.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.5.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.5-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.5&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.5.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CLINICAL EVALUATION (N=98) OF CHITOSAN-COVERED (CELOX PPH) GAUZE IN PATIENTS WITH PPH<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p><strong>Use of CELOX&#x2122; PPH in 98 cases of severe postpartum haemorrhage\u2013a multicenter registry analysis.<\/strong><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Von Beckerath AK, Maul H, Gebauer G, Abdel-Kawi AF, Rolf N, Saade G, Bader W, Kusnierczak D, Berger R, Kienast C, Kienemund J, Schmid B. Am J Obstet Gynecol. 2016; 214(1 Suppl 1):S269. [poster presentation]<\/p>\n<p>Multicentre registry analysis study (n=98)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Assessment of the potential side effects of CELOX&#x2122; PPH, and to assess if the use of CELOX&#x2122; PPH reduces the rate of postpartum hysterectomies<\/li>\n<li>Women with PPH were treated in accordance to guidelines with the addition of uterine packing using CELOX&#x2122; PPH<\/li>\n<li>After the introduction of CELOX&#x2122; PPH the rate of postpartum hysterectomies reduced from 0.18% to 0.05% (p=0.0183)<\/li>\n<li>No adverse events were observed or reported<\/li>\n<li>CELOX&#x2122; PPH is cost-effective and easy to use<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.6.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.5-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.5&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.6.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CLINICAL EVALUATION (N=65) OFCHITOSAN-COVERED (CELOX PPH) GAUZE IN PATIENTS WITH SEVERE PPH (INCLUDING CASES WHERE RISK OF POSTPARTUM HYSTERECTOMY IS HIGH)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Uterine packing with CELOX&#x2122; PPH for control of postpartum Haemorrhage (PPH).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Maul H, Steinmacher S, Saade G, Gebauer G, Rolf N, Schmid B. Am J Obstet Gynecol. 2015; 212(1 Suppl 1):S358-S359. [poster presentation]<\/p>\n<p>Case study series (n=65)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Objective: to compare a 26 month period before and a 38 month period after the introduction of CELOX&#x2122; PPH in the treatment of PPH<\/li>\n<li>Women with PPH were treated by uterine packing with CELOX&#x2122; PPH through the hysterotomy in caesarean delivery, or transvaginally<\/li>\n<li>CELOX&#x2122; PPH is a viable option in the treatment of PPH<\/li>\n<li>After the introduction of CELOX&#x2122; PPH postpartum hysterectomies were significantly reduced (p=0.023)<\/li>\n<li>CELOX&#x2122; PPH can be safely used after both vaginal and caesarean section<\/li>\n<li>No complications related to CELOX&#x2122; PPH treatment were observed<\/li>\n<li>The use of CELOX&#x2122; PPH is inexpensive<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.7.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.7-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.7&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.7.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CLINICAL EVALUATION (N=35) OF CHITOSAN-COVERED (CELOX&#x2122; PPH) GAUZE IN PATIENTS WITH PPH<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Uterine packing with CELOX&#x2122; PPH for control of postpartum Haemorrhage.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Maul H, Gebauer G, Rolf N, Saade G, Rezniczek G, Schmid B. Am J Obstet Gynecol. 2014; 210(1 Suppl 1):S281-S282. [poster presentation]<\/p>\n<p>Case study series (n=35)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Objective: to describe 26 months of experience using CELOX&#x2122; PPH in the treatment of PPH<\/li>\n<li>Over comparable periods of time (26 months) and similar number of births (n=5498 vs. n=6222) before and after the introduction of CELOX&#x2122; PPH there was a significant reduction in the rate of postpartum hysterectomies (p=0.011)<\/li>\n<li>CELOX&#x2122; PPH is a viable option for the treatment of (severe) PPH<\/li>\n<li>CELOX&#x2122; PPH is easy to apply and can be used after both vaginal and caesarean deliveries and requires no special training<\/li>\n<li>CELOX&#x2122; PPH is inexpensive compared to other treatment options<\/li>\n<li>No complications related to CELOX&#x2122; PPH treatment were observed<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.8.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.8-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.8&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.8.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CASE STUDIES: USE OF CELOX&#x2122; PPH IN PATIENTS (N=19) WITH SEVERE PPH (INCLUDING CASES WHERE RISK OF POSTPARTUM HYSTERECTOMY IS HIGH)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Uterine packing with CELOX&#x2122; PPH for control of postpartum Haemorrhage.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Schmid BC, Rezniczek GA, Rolf N, Saade G, Gebauer G, Maul H.. Am J Obstet Gynecol. 2013; 209(3):225.e1-225.e5.<\/p>\n<p>Case study series (n=19)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Assessment of the use of CELOX&#x2122; PPH in the treatment of PPH<\/li>\n<li>Women with PPH were treated with uterine packing using CELOX&#x2122; PPH either through the hysterotomy, in the case of caesarean delivery or transvaginally<\/li>\n<li>In all but one case (18\/19) bleeding was halted and no further intervention was required<\/li>\n<li>Over equivalent 18-month periods and with a comparable number of births (3822 vs. 4077) before and after the introduction of CELOX&#x2122; PPH, the rate of peripartum hysterectomies was reduced by 75% (p = .044)<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.9.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.8-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.8&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.9.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CASE STUDIES: USE OF CHITOSAN (CELOX&#x2122; PPH GAUZE) IN PATIENTS WITH (N=4) LIFE-THREATENING OBSTETRIC BLEEDING<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Uses of CELOX&#x2122; PPH for treating different forms of serious obstetrics haemorrhages.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Carles G, Dabiri C, Mchirgui A, Saoudi EO, Hcini N, Pouget K, Seve B, de Matteis B. J Gynecol Obstet Hum Reprod. 2017; 46(9):693-695.<\/p>\n<p>Case study series (n=4)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Four cases where CELOX&#x2122; PPH was used to treat severe obstetric haemorrhage<\/li>\n<li>Two chitosan variants, in powder and CELOX&#x2122; PPH form, were used*<\/li>\n<li>In all four cases, chitosan effectively resolved the severe obstetric haemorrhage<\/li>\n<li>Treatment with CELOX PPH was inexpensive, and required no training<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.10.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.10-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.10&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.10.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CASE REPORT: USE OF CHITOSAN-COVERED (CELOX&#x2122; PPH) GAUZE IN COMBINATION WITH BALLOON TAMPONADE FOR MANAGEMENT OF PPH<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Application of CELOX&#x2122; PPH in combination with intrauterine balloon tamponade for postpartum Haemorrhage treatment \u2013 Case report of a novel \u00abuterine sandwich\u00bb approach.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Seidel V, Braun T, Weizs\u00e4cker K, Henrich W. Int J Surg Case Rep. 2018; 48:101-103.<\/p>\n<p>Case report (n=1)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Presentation of a case of PPH where a novel \u201cuterine sandwich\u201d (a combination of CELOX&#x2122; PPH and intrauterine balloon tamponade) used to halt blood loss<\/li>\n<li>The novel treatment strategy was effective at stopping further blood loss<\/li>\n<li>The use of the \u201cuterine sandwich\u201d prevented the need for more invasive second stage intervention<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.11.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Monograph-Nov-2023-4.3.11-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Monograph-Nov-2023-4.3.11&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Monograph-Nov-2023-4.3.11.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>CASE REPORT: USE OF HAEMOSTATIC COMBAT (CELOX&#x2122; PPH) GAUZE IN A SEVERE CASE OF PPH<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Postpartum Haemorrhage: use of CELOX&#x2122; PPH.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Schmid BC, Rezniczek GA, Rolf N, Maul H. Am J Obstet Gynecol. 2012; 206(1):e12-e13.<\/p>\n<p>Case report (n=1)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<ul>\n<li>Reporting of a case of PPH where conservative treatment proved ineffective, and CELOX&#x2122; PPH was used<\/li>\n<li>Tight uterovaginal packing with CELOX&#x2122; PPH was performed in an effort to arrest recurring haemorrhage<\/li>\n<li>CELOX&#x2122; PPH achieved haemostasis and remained in place for 36 hours*<\/li>\n<li>By achieving haemostasis, CELOX&#x2122; PPH prevented a seemingly inevitable hysterectomy<\/li>\n<li>The ease of application and cost-effectiveness of CELOX&#x2122; PPH present a promising addition to the treatment options for PPH<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_4,3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb border_color_all=\u00bb#d8d8d8&#8243; border_width_bottom=\u00bb7px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_icon font_icon=\u00bb&#x22;||divi||400&#8243; url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Evidence-AJOG.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_icon][et_pb_image src=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/04\/Celox-PPH-Evidence-AJOG-pdf.jpg\u00bb title_text=\u00bbCelox-PPH-Evidence-AJOG\u00bb url=\u00bbhttps:\/\/adaro.es\/CeloxPPH\/wp-content\/uploads\/2024\/07\/Celox-PPH-Evidence-AJOG.pdf\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb box_shadow_style=\u00bbpreset3&#8243; global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb3_4&#8243; _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb27px\u00bb text_line_height=\u00bb1.1em\u00bb custom_margin=\u00bb||11px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>UTERINE PACKING WITH CHITOSAN-COVERED TAMPONADE TO TREAT POSTPARTUM HEMORRHAGE<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|600|||||||\u00bb text_font_size=\u00bb19px\u00bb custom_margin=\u00bb||22px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>American Journal of Obstetrics &amp; Gynecology &#8211; Expert Review<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb20px\u00bb text_line_height=\u00bb1.2em\u00bb custom_margin=\u00bb-4px||13px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Wolfgang Henrich, MD, PhD; Anna Du\u00a8ckelmann, MD; Thorsten Braun, MD, PhD;<br \/>Larry Hinkson, MBBS, MD, MRCOG, FRCOG<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bb|300|||||||\u00bb text_font_size=\u00bb19px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p>Postpartum hemorrhage (PPH) causes substantial maternal mortality and morbidity and is responsible for a quarter of all maternal deaths worldwide.1 Conventional use of uterotonics such as oxytocin, prostaglandins, and medications to support coagulation, such as fibrinogen and tranexamic acid, are helpful but may not be sufficient to arrest life-threatening PPH. Blood transfusions, intrauterine balloon tamponade application, invasive techniques, such as compression sutures, and arterial ligation are advanced steps in the management cascade. In extreme cases, a hysterectomy may be necessary to avoid maternal death.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CELOX&#x2122; PPHUna d\u00e9cada de resultados confiables en entornos de atenci\u00f3n m\u00e9dica del mundo real para un control y tratamiento altamente efectivo de la HPP uterina &nbsp;ACCI\u00d3NR\u00c1PIDASEGURO\u00a0Y CL\u00cdNICAMENTE EFICAZVERS\u00c1TIL\u00a0Y F\u00c1CIL DE USAR12 a\u00f1os de eficacia cl\u00ednica (dentro de aplicaciones de HPP) frente al est\u00e1ndar de atenci\u00f3n, lo que demuestra una tecnolog\u00eda segura y cl\u00ednicamente eficazLos datos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-19","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/pages\/19","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/comments?post=19"}],"version-history":[{"count":15,"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/pages\/19\/revisions"}],"predecessor-version":[{"id":108,"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/pages\/19\/revisions\/108"}],"wp:attachment":[{"href":"https:\/\/adaro.es\/CeloxPPH\/wp-json\/wp\/v2\/media?parent=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}